NKX3-1 and benign prostatic hyperplasia: This resulted in the validation of two novel PCa biomarkers - GLO1 and NKX3-1 mRNAs that are overexpressed in PCa tissues, known to functionally contribute to the PCa development, and have higher levels in plasma EVs from PCa patients than BPH patients.